BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 23319559)

  • 1. Antibodies to Escherichia coli-expressed C-terminal domains of Plasmodium falciparum variant surface antigen 2-chondroitin sulfate A (VAR2CSA) inhibit binding of CSA-adherent parasites to placental tissue.
    Saveria T; Oleinikov AV; Wiliamson K; Chaturvedi R; Lograsso J; Keitany GJ; Fried M; Duffy P
    Infect Immun; 2013 Apr; 81(4):1031-9. PubMed ID: 23319559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure of the DBL3X-DBL4ε region of the VAR2CSA placental malaria vaccine candidate: insight into DBL domain interactions.
    Gangnard S; Lewit-Bentley A; Dechavanne S; Srivastava A; Amirat F; Bentley GA; Gamain B
    Sci Rep; 2015 Oct; 5():14868. PubMed ID: 26450557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Var2CSA DBL6-epsilon domain expressed in HEK293 induces limited cross-reactive and blocking antibodies to CSA binding parasites.
    Fernandez P; Viebig NK; Dechavanne S; Lépolard C; Gysin J; Scherf A; Gamain B
    Malar J; 2008 Sep; 7():170. PubMed ID: 18771584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with recombinant duffy binding-like-gamma3 induces pan-reactive and adhesion-blocking antibodies against placental chondroitin sulfate A-binding Plasmodium falciparum parasites.
    Costa FT; Fusaï T; Parzy D; Sterkers Y; Torrentino M; Douki JB; Traoré B; Petres S; Scherf A; Gysin J
    J Infect Dis; 2003 Jul; 188(1):153-64. PubMed ID: 12825185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strain-transcendent immune response to recombinant Var2CSA DBL5-ε domain block P. falciparum adhesion to placenta-derived BeWo cells under flow conditions.
    Fernandez P; Petres S; Mécheri S; Gysin J; Scherf A
    PLoS One; 2010 Sep; 5(9):e12558. PubMed ID: 20838433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of VAR2CSA domain-specific inhibitory antibodies of the Plasmodium falciparum erythrocyte membrane protein 1 using a novel flow cytometry assay.
    Obiakor H; Avril M; Macdonald NJ; Srinivasan P; Reiter K; Anderson C; Holmes KL; Fried M; Duffy PE; Smith JD; Narum DL; Miller LH
    Clin Vaccine Immunol; 2013 Mar; 20(3):433-42. PubMed ID: 23345587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multilaboratory approach to preclinical evaluation of vaccine immunogens for placental malaria.
    Fried M; Avril M; Chaturvedi R; Fernandez P; Lograsso J; Narum D; Nielsen MA; Oleinikov AV; Resende M; Salanti A; Saveria T; Williamson K; Dicko A; Scherf A; Smith JD; Theander TG; Duffy PE
    Infect Immun; 2013 Feb; 81(2):487-95. PubMed ID: 23208604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designing a VAR2CSA-based vaccine to prevent placental malaria.
    Fried M; Duffy PE
    Vaccine; 2015 Dec; 33(52):7483-8. PubMed ID: 26469717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single full-length VAR2CSA ectodomain variant purifies broadly neutralizing antibodies against placental malaria isolates.
    Doritchamou JYA; Renn JP; Jenkins B; Mahamar A; Dicko A; Fried M; Duffy PE
    Elife; 2022 Feb; 11():. PubMed ID: 35103596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of Duffy binding-like domains that bind chondroitin sulfate A and protection against pregnancy-associated malaria.
    Bir N; Yazdani SS; Avril M; Layez C; Gysin J; Chitnis CE
    Infect Immun; 2006 Oct; 74(10):5955-63. PubMed ID: 16988275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with VAR2CSA-DBL5 recombinant protein elicits broadly cross-reactive antibodies to placental Plasmodium falciparum-infected erythrocytes.
    Avril M; Cartwright MM; Hathaway MJ; Hommel M; Elliott SR; Williamson K; Narum DL; Duffy PE; Fried M; Beeson JG; Smith JD
    Infect Immun; 2010 May; 78(5):2248-56. PubMed ID: 20194590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional and immunological characterization of the var2CSA-DBL5epsilon domain of a placental Plasmodium falciparum isolate.
    Gangnard S; Tuikue Ndam NG; Gnidehou S; Quiviger M; Juillerat A; Faure G; Baron B; Viwami F; Deloron P; Bentley GA
    Mol Biochem Parasitol; 2010 Oct; 173(2):115-22. PubMed ID: 20562018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chondroitin sulphate A (CSA)-binding of single recombinant Duffy-binding-like domains is not restricted to Plasmodium falciparum Erythrocyte Membrane Protein 1 expressed by CSA-binding parasites.
    Resende M; Ditlev SB; Nielsen MA; Bodevin S; Bruun S; Pinto VV; Clausen H; Turner L; Theander TG; Salanti A; Dahlbäck M
    Int J Parasitol; 2009 Sep; 39(11):1195-204. PubMed ID: 19324047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VAR2CSA Domain-Specific Analysis of Naturally Acquired Functional Antibodies to Plasmodium falciparum Placental Malaria.
    Doritchamou JY; Herrera R; Aebig JA; Morrison R; Nguyen V; Reiter K; Shimp RL; MacDonald NJ; Narum DL; Fried M; Duffy PE
    J Infect Dis; 2016 Aug; 214(4):577-86. PubMed ID: 27190180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural insights into chondroitin sulphate A binding Duffy-binding-like domains from Plasmodium falciparum: implications for intervention strategies against placental malaria.
    Gill J; Chitnis CE; Sharma A
    Malar J; 2009 Apr; 8():67. PubMed ID: 19374733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of strain-transcendent antibodies to placental-type isolates with VAR2CSA DBL3 or DBL5 recombinant proteins.
    Avril M; Cartwright MM; Hathaway MJ; Smith JD
    Malar J; 2011 Feb; 10():36. PubMed ID: 21314945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Full-length recombinant Plasmodium falciparum VAR2CSA binds specifically to CSPG and induces potent parasite adhesion-blocking antibodies.
    Khunrae P; Dahlbäck M; Nielsen MA; Andersen G; Ditlev SB; Resende M; Pinto VV; Theander TG; Higgins MK; Salanti A
    J Mol Biol; 2010 Apr; 397(3):826-34. PubMed ID: 20109466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential induction of functional IgG using the Plasmodium falciparum placental malaria vaccine candidate VAR2CSA.
    Pinto VV; Ditlev SB; Jensen KE; Resende M; Dahlbäck M; Andersen G; Andersen P; Theander TG; Salanti A; Nielsen MA
    PLoS One; 2011 Mar; 6(3):e17942. PubMed ID: 21464946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Murine Model for Preclinical Studies of Var2CSA-Mediated Pathology Associated with Malaria in Pregnancy.
    de Moraes LV; Dechavanne S; Sousa PM; Barateiro A; Cunha SF; Nunes-Silva S; Lima FA; Murillo O; Marinho CRF; Gangnard S; Srivastava A; Braks JA; Janse CJ; Gamain B; Franke-Fayard B; Penha-Gonçalves C
    Infect Immun; 2016 Jun; 84(6):1761-1774. PubMed ID: 27045035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequestration of Plasmodium falciparum-infected erythrocytes to chondroitin sulfate A, a receptor for maternal malaria: monoclonal antibodies against the native parasite ligand reveal pan-reactive epitopes in placental isolates.
    Lekana Douki JB; Traore B; Costa FT; Fusaï T; Pouvelle B; Sterkers Y; Scherf A; Gysin J
    Blood; 2002 Aug; 100(4):1478-83. PubMed ID: 12149234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.